Activin and Inhibin

Bay 65-1942 hydrochloride is an ATP-competitive and selective IKKβ inhibitor.In VitroDelivery of Bay 65-1942 prior to ischemia significantly decreases left ventricular infarct size compared with animals receiving vehicle. Compared with sham animals,

Bay 65-1942 hydrochloride is an ATP-competitive and selective IKKβ inhibitor.In VitroDelivery of Bay 65-1942 prior to ischemia significantly decreases left ventricular infarct size compared with animals receiving vehicle. Compared with sham animals,

Bay 65-1942 hydrochloride is an ATP-competitive and selective IKKβ inhibitor.In VitroDelivery of Bay 65-1942 prior to ischemia significantly decreases left ventricular infarct size compared with animals receiving vehicle. Compared with sham animals,

Bay 65-1942 hydrochloride is an ATP-competitive and selective IKKβ inhibitor.In VitroDelivery of Bay 65-1942 prior to ischemia significantly decreases left ventricular infarct size compared with animals receiving vehicle. Compared with sham animals,

Bay 65-1942 hydrochloride is an ATP-competitive and selective IKKβ inhibitor.In VitroDelivery of Bay 65-1942 prior to ischemia significantly decreases left ventricular infarct size compared with animals receiving vehicle. Compared with sham animals,

BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP) , with high potency ( IC 50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressureIn VivoBAY 73-1449

BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitorIn VitroThe BAY 73-6691 dose-dependently alleviates cell viability loss due to Aβ 25-35 treatment. It is found that when SH-SY5Y cells are cultured by Aβ 25-35

BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitorIn VitroThe BAY 73-6691 dose-dependently alleviates cell viability loss due to Aβ 25-35 treatment. It is found that when SH-SY5Y cells are cultured by Aβ 25-35

BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitorIn VitroThe BAY 73-6691 dose-dependently alleviates cell viability loss due to Aβ 25-35 treatment. It is found that when SH-SY5Y cells are cultured by Aβ 25-35

BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitorIn VitroThe BAY 73-6691 dose-dependently alleviates cell viability loss due to Aβ 25-35 treatment. It is found that when SH-SY5Y cells are cultured by Aβ 25-35

BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitorIn VitroThe BAY 73-6691 dose-dependently alleviates cell viability loss due to Aβ 25-35 treatment. It is found that when SH-SY5Y cells are cultured by Aβ 25-35

BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitorIn VitroThe BAY 73-6691 dose-dependently alleviates cell viability loss due to Aβ 25-35 treatment. It is found that when SH-SY5Y cells are cultured by Aβ 25-35